Search the Newsreel

MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Analysts

MBX Biosciences, Inc. (NASDAQ:MBX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $66.75. This recommendation is based on nine buy ratings, one strong-buy, and two sell ratings. Several institutional investors have recently increased their holdings in …

MBX Biosciences Inc Today's Market Trends | MBX Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

MBX Biosciences Inc (MBX) is currently trading at $60.02, down 2.09% today, but showing significant gains over the past year. The company, a clinical-stage biopharmaceutical firm focusing on endocrine and metabolic disorders, has a "Buy" rating from analysts with an average target price of …

EcoR1 Capital LLC Decreases Stock Position in MBX Biosciences, Inc. $MBX

EcoR1 Capital LLC significantly reduced its stake in MBX Biosciences (NASDAQ:MBX) by 63.4% during Q1, selling 1.35 million shares but still holding 777,000 shares valued at $23.2 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $66.75, with …

MBX Biosciences Inc (MBX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of MBX Biosciences Inc (MBX), focusing on its profitability and balance sheet. As of the close on July 27, the company's stock was trading at $61.267, experiencing a slight decline of 1.18%. Key financial indicators like market capitalization …

MBX Biosciences, Inc. $MBX is Orbimed Advisors LLC's 10th Largest Position

Orbimed Advisors LLC recently reduced its stake in MBX Biosciences by 7.6%, but it still holds 3.64 million shares, making it their 10th largest position. Despite Orbimed’s reduction, other institutional investors, such as Russell Investments and Royal Bank of Canada, increased their holdings. MBX …

MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MBX Biosciences Inc. (MBX) stock, focusing on its dividend and stock split history. It notes that the company has distributed no dividends over the past five years. Key financial data like market capitalization and recent stock performance are …

MBX Biosciences, Inc. Revenue Breakdown – NASDAQ:MBX

This article provides details for accessing financial information, including revenue breakdown, for MBX Biosciences, Inc. (NASDAQ:MBX) on TradingView. It highlights the availability of fundamentals, stats, and various financial statements for the biotechnology company. The content primarily serves as a directory for users interested in …

MBX|MBX Biosciences Inc|Price:62.000|Chg%:-1.570

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The article provides an overview of the company's product candidates, including MBX 2109, MBX 1416, and its Obesity portfolio, designed for conditions like hypoparathyroidism and …

MBX|MBX Biosciences Inc|Price:66.248|Chg%:-1.572

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The article provides an overview of the company's product candidates, including MBX 2109, MBX 1416, and its Obesity portfolio, designed for conditions like hypoparathyroidism and …

UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90

UBS has reiterated its Buy rating on MBX Biosciences (MBX.US) and maintained its target price at $90. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.

MBX Biosciences stock hits all-time high at 66.66 USD

MBX Biosciences Inc. stock reached an all-time high of $66.66, reflecting a 336.31% gain over the past year and more than 101% year-to-date. Despite appearing slightly overvalued according to InvestingPro, the company has seen leadership changes and positive Phase 2 and Phase 1/2a trial …

MBX Biosciences (NASDAQ:MBX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen has downgraded MBX Biosciences (NASDAQ:MBX) from a "hold" to a "sell" rating, despite other analysts like Barclays, Truist Financial, and Citizens JMP recently increasing their price targets. The stock currently holds a "Moderate Buy" consensus rating with a $63.00 target price. …

MBX Biosciences (MBX) price target increased by 11.23% to 69.55

MBX Biosciences (MBX) has seen its price target increased by 11.23%, bringing it to $69.55. This adjustment reflects a positive outlook on the company's financial prospects and stock valuation.

Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge?

MBX Biosciences (MBX) has appointed Steve Hoerter as CEO and Chairman, alongside John Smither as CFO, following a significant surge in stock price. The company's P/B ratio of 6.3x is considered overvalued compared to the broader US pharmaceutical industry but favorable against a peer …

MBX Biosciences (NASDAQ:MBX) Trading 5.1% Higher - What's Next?

MBX Biosciences (NASDAQ:MBX) shares increased by 5.1% on Friday, trading as high as $60.11 and closing at $61.30, despite a significant drop in trading volume. Analysts maintain a generally positive outlook, with a consensus "Moderate Buy" rating and an average price target of $63.00, …

How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment Narrative

MBX Biosciences has appointed Steve Hoerter as CEO and Chairman and John Smither as CFO, effective July 13, 2026. This leadership change brings experienced individuals to the helm, who are expected to reframe the company's investment narrative and influence its financial discipline and execution …

MBX Biosciences Announces CEO Transition and Leadership Updates

MBX Biosciences announced a leadership transition, with CEO Kent P. Hawryluk stepping down on July 13, 2026. Steven Hoerter has been named the new President, CEO, and principal executive officer, while John Smither is confirmed as CFO. The company's stock currently holds a "Buy" …

Carmel-based MBX Biosciences makes leadership changes

MBX Biosciences, a Carmel-based biotechnology firm, has shuffled its leadership team, moving founder Richard DiMarchi from CEO to Chief Scientific Officer and appointing Paul Hargreaves as the new CEO. The company also announced the addition of Orville Kolterman and Heather Hirsch as board directors. …

Microbix Biosystems Leads These 3 Promising Penny Stocks On TSX

Subdued Growth No Barrier To Microbix Biosystems Inc.'s (TSE:MBX) Price

Microbix Biosystems Inc. (MBX.TO) Valuation Measures & Financial Statistics